多参数MRI预测临界可切除或局部晚期胰腺癌新辅助FOLFIRINOX治疗反应
该前瞻性研究纳入41例临界可切除或局部晚期胰腺导管腺癌患者,于FOLFIRINOX治疗前及第二周期后行多参数MRI,发现基线ΔR1是肿瘤反应和生存的独立预测因子,ΔR1≥1.31 s-1可进行预后分层。
要点
- 基线ΔR1是肿瘤反应的唯一独立预测因子(校正OR 31.07,p=0.008)。
- 基线ΔR1≥1.31 s-1者中位PFS 16.0个月、中位OS 34.9个月,优于低于阈值者的10.0个月和16.6个月。
- 基线ΔR1也是PFS的独立预测因子(校正HR 0.40,p=0.033),R0切除同样为独立预测因子。
关键影像表现/征象
- MRI评估包括动态对比增强MRI、体素内不相干运动扩散加权成像、T2*弛豫率R2*及肿瘤ΔR1(平衡期R1减去增强前R1)。
- 基线ΔR1是肿瘤反应的唯一独立预测因子(校正OR 31.07,p=0.008)。
诊断标准与关键数值
- 基线ΔR1以≥1.31 s-1为截断值可进行预后分层:中位PFS 16.0个月 vs 10.0个月(p=0.029),中位OS 34.9个月 vs 16.6个月(p=0.023)。
- 基线ΔR1预测肿瘤反应:校正OR 31.07(p=0.008)。
- 基线ΔR1预测PFS:校正HR 0.40(p=0.033)。
临床应用与阅片要点
- 作者认为基线ΔR1值可能有助于预测接受新辅助FOLFIRINOX治疗的临界可切除或局部晚期胰腺导管腺癌患者的肿瘤反应和生存。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To identify multiparametric MRI biomarkers to predict the tumor response to neoadjuvant FOLFIRINOX therapy in patients with borderline resectable (BR) or locally advanced (LA) pancreatic ductal adenocarcinoma (PDAC).
METHODS: From May 2016 to March 2018, adult patients with BR or LA PDAC were prospectively enrolled in this study. They received eight cycles of FOLFIRINOX therapy and underwent multiparametric MRI twice (at baseline and after the second cycle). MRI evaluations included dynamic contrast-enhanced MRI, intravoxel incoherent motion diffusion-weighted imaging, and assessment of T2* relaxivity (R2*) and the change in T1 relaxivity (ΔR1, equilibrium phase R1 minus non-enhanced R1) of the tumors. Factors to predict the responders determined by the best overall response during FOLFIRINOX therapy and those to predict progression-free survival (PFS) and overall survival (OS) were evaluated using multivariable logistic regression and the Cox proportional hazard model.
RESULTS: Forty-one patients (mean age, 60.3 years ± 9.3; 24 men) were included. Among the clinical and MRI factors, the baseline ΔR1 (adjusted odds ratio, 31.07; p = 0.008) was the only independent predictor for tumor response. The baseline ΔR1 was also an independent predictor for PFS (adjusted hazard ratio, 0.40; p = 0.033) along with R0 resection. The use of a cutoff ΔR1 value of ≥ 1.31 s-1 enabled prognostic stratification (median PFS, 16.0 months vs.10.0 months; p = 0.029; median OS, 34.9 months vs. 16.6 months; p = 0 .023, respectively).
CONCLUSIONS: The baseline tumor ΔR1 value may be useful to predict tumor response and survival in patients with BR or LA PDAC receiving FOLFIRINOX neoadjuvant therapy.
KEY POINTS: • Baseline ΔR1 was an independent predictor for tumor response (adjusted odds ratio, 31.07; p = 0.008) and progression-free survival (adjusted hazard ratio, 0.40; p = 0.033) in patients with borderline resectable or locally advanced pancreatic ductal adenocarcinoma receiving neoadjuvant FOLFIRINOX therapy. • The criterion of baseline ΔR1 value ≥ 1.31 s-1 allowed for the prediction of favorable tumor response and survival outcome after neoadjuvant FOLFIRINOX therapy.
引用
- Kang JH, Lee SS, Kim JH, et al. Multiparametric MRI for prediction of treatment response to neoadjuvant FOLFIRINOX therapy in borderline resectable or locally advanced pancreatic cancer. Eur Radiol. 2020. PMID: 32813104. doi:10.1007/s00330-020-07134-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。